Give IPR the Green Light | Association for Accessible Medicines
Welcome Message - Blog from AAM President and CEO Dan Leonard: Generics: The Bridge to A Vaccine.

Give IPR the Green Light

Congress created Inter Partes Review (IPR) to improve patent quality and expedite access to safe and affordable generic and biosimilar medicines. IPR is a process that allows patent experts to take a second look at patents and ensure that every granted patent represents true innovation. This graphic demonstrates how IPR improves patent quality, accelerates competition and makes lower-cost generics and biosimilars accessible to U.S. patients. Learn more in this infographic:

Download Infographic

Take action now:


AAM White Paper First Generics

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.